Takeda's evolution continues
By Eo, Yun-Ho | translator Choi HeeYoung
21.02.15 17:56:53
가나다라
0
Completion of follow-up measures after the sale of the division, strengthening the capacity of anticancer drugs and rare diseases
Focusing on improving patient access, such as EAP, the conservative attitude of the Cancer Disease Review Committee is disappointing
▲Moon Hee-seok, CEO
It is difficult to stop what is going well. Even more so if it is a company's business.Takeda sold its diabetes and over-the-counter (OTC) business to Celltrion, a domestic company, last year. Takeda's Actos is a TZD-family drug that persisted in the Avandia outbreak, while Whituben and Albothyl are famous OTCs that everyone knows, meaning they sold the products that symbolized the company.
Takeda has carried out a total of four mergers and acquisitions: Millenium Pharmaceutical in 2008, Nycomed in 2012, ARIAD Pharmaceuticals in 2017, and Shire in 2018. Pipelines have been reinforced in the areas of anticancer drugs, rare diseases, and gastrointestinal diseases. The situation is rapidl
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)